ADAR1 Capital Management’s UroGen Pharma URGN Stock Holding History

ADAR1 Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.29M	Sell	252,395 -143,064	-36%	-$3.88M	0.43%	56
2026 Q1	$7.11M	Buy	395,459 +270,084	+215%	+$5.41M	0.42%	58
2025 Q4	$2.94M	Buy	125,375 +90,375	+258%	+$1.96M	0.22%	83
2025 Q3	$698K	Buy	35,000 +25,000	+250%	+$449K	0.07%	118
2025 Q2	$137K	Buy	+10,000	New	+$96K	0.02%	165

Other funds holding URGN

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

ADAR1 Capital Management's URGN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its UroGen Pharma (URGN) stake by 36% in Q2 2026, selling an estimated $3.88M and leaving 252,395 shares worth $9.29M. The position accounts for 0.43% of the portfolio, ranked #56.

ADAR1 Capital Management first reported a position in URGN in Q2 2025 and has held it in 5 quarters since. 189 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

ADAR1 Capital Management held 252,395 shares of UroGen Pharma worth $9.29M as of Q2 2026.
ADAR1 Capital Management sold 143,064 UroGen Pharma shares in Q2 2026, an estimated $3.88M.
UroGen Pharma made up 0.43% of ADAR1 Capital Management's portfolio in Q2 2026, its #56 holding.
ADAR1 Capital Management first reported a position in UroGen Pharma in Q2 2025 and has held it in 5 quarters since.
189 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.